Venous Thromboembolism in Rheumatoid Arthritis: The Added Effect of Disease Activity to Traditional Risk Factors

References

• White RH. The epidemiology of venous thromboembolism. Circulation. 2003;107(23 Suppl 1):I4–8. doi:10.1161/01.CIR.0000078468.11849.66
   PubMed Web of Science ®Google Scholar
• Ungprasert P, Srivali N, Spanuchart I, Thongprayoon C, Knight EL. Risk of venous thromboembolism in patients with rheumatoid arthritis: a systematic review and meta-analysis. Clin Rheumatol. 2014;33(3):297–304. doi:10.1007/s10067-014-2492-7
   PubMed Web of Science ®Google Scholar
• Hu LJ, Ji B, Fan HX. Venous thromboembolism risk in rheumatoid arthritis patients: a systematic review and updated meta-analysis. Eur Rev Med Pharmacol Sci. 2021;25(22):7005–7013. doi:10.26355/eurrev_202111_27249
   PubMed Web of Science ®Google Scholar
• Xu B, Lin J. Characteristics and risk factors of rheumatoid arthritis in the United States: an NHANES analysis. PeerJ. 2017;5:e4035. doi:10.7717/peerj.4035
   PubMed Web of Science ®Google Scholar
• Stein PD, Hull RD, Kayali F, Ghali WA, Alshab AK, Olson RE. Venous thromboembolism according to age: the impact of an aging population. Arch Intern Med. 2004;164(20):2260–2265. doi:10.1001/archinte.164.20.2260
   PubMedGoogle Scholar
• Lu B, Hiraki LT, Sparks JA, et al. Being overweight or obese and risk of developing rheumatoid arthritis among women: a prospective cohort study. Ann Rheum Dis. 2014;73(11):1914–1922. doi:10.1136/annrheumdis-2014-205459
   PubMed Web of Science ®Google Scholar
• Rahmani J, Haghighian Roudsari A, Bawadi H, et al. Relationship between body mass index, risk of venous thromboembolism and pulmonary embolism: a systematic review and dose-response meta-analysis of cohort studies among four million participants. Thromb Res. 2020;192:64–72. doi:10.1016/j.thromres.2020.05.014
   PubMed Web of Science ®Google Scholar
• Sugiyama D, Nishimura K, Tamaki K, et al. Impact of smoking as a risk factor for developing rheumatoid arthritis: a meta-analysis of observational studies. Ann Rheum Dis. 2010;69(1):70–81. doi:10.1136/ard.2008.096487
   PubMed Web of Science ®Google Scholar
• Zhang G, Xu X, Su W, Xu Q. Smoking and risk of venous thromboembolism: a systematic review. Southeast Asian J Trop Med Public Health. 2014;45(3):736–745.
   PubMed Web of Science ®Google Scholar
• Anderson FA, Spencer FA. Risk factors for venous thromboembolism. Circulation. 2003;107(23 Suppl 1):I9–16. doi:10.1161/01.CIR.0000078469.07362.E6
   PubMed Web of Science ®Google Scholar
• Smolen JS. Treat-to-target: rationale and strategies. Clin Exp Rheumatol. 2012;30(4 Suppl 73):S2–6.
   PubMed Web of Science ®Google Scholar
• Curtis JR, Singh JA. Use of biologics in rheumatoid arthritis: current and emerging paradigms of care. Clin Ther. 2011;33(6):679–707. doi:10.1016/j.clinthera.2011.05.044
   PubMed Web of Science ®Google Scholar
• Kragstrup TW, Glintborg B, Svensson AL, et al. Waiting for JAK inhibitor safety data. RMD Open. 2022;8(1):e002236. doi:10.1136/rmdopen-2022-002236
   PubMed Web of Science ®Google Scholar
• Roderick P, Ferris G, Wilson K, et al. Towards evidence-based guidelines for the prevention of venous thromboembolism: systematic reviews of mechanical methods, oral anticoagulation, dextran and regional anaesthesia as thromboprophylaxis. Health Technol Assess. 2005;9(49):iii–iv, ix–x, 1–78. doi:10.3310/hta9490
   Web of Science ®Google Scholar
• Greenall R, Davis RE. Intermittent pneumatic compression for venous thromboembolism prevention: a systematic review on factors affecting adherence. BMJ Open. 2020;10(9):e037036. doi:10.1136/bmjopen-2020-037036
   PubMed Web of Science ®Google Scholar
• Lau BD, Murphy P, Nastasi AJ, et al. Effectiveness of ambulation to prevent venous thromboembolism in patients admitted to hospital: a systematic review. CMAJ Open. 2020;8(4):E832–e843. doi:10.9778/cmajo.20200003
   PubMedGoogle Scholar
• Hong J, Ahn SY, Lee YJ, et al. Updated recommendations for the treatment of venous thromboembolism. Blood Res. 2021;56(1):6–16. doi:10.5045/br.2021.2020083
   PubMed Web of Science ®Google Scholar
• Konstantinides SV, The MG. 2019 ESC Guidelines on the Diagnosis and Management of Acute Pulmonary Embolism. Eur Heart J. 2019;40(42):3453–3455. doi:10.1093/eurheartj/ehz726
   PubMed Web of Science ®Google Scholar
• Ackerknecht EH, Virchow R. Doctor, Statesman, Anthro-Pologist. University of Wisconsin, Madison; 1953.
   Google Scholar
• Mammen EF. Pathogenesis of venous thrombosis. Chest. 1992;102(6 Suppl):640s–644s. doi:10.1378/chest.102.6_Supplement.640S
   PubMed Web of Science ®Google Scholar
• van Drongelen V, Holoshitz J. Human Leukocyte Antigen-Disease Associations in Rheumatoid Arthritis. Rheum Dis Clin North Am. 2017;43(3):363–376. doi:10.1016/j.rdc.2017.04.003
   PubMed Web of Science ®Google Scholar
• Lin YJ, Anzaghe M, Schulke S. Update on the pathomechanism, diagnosis, and treatment options for rheumatoid arthritis. Cells. 2020;9(4). doi:10.3390/cells9040880
   Web of Science ®Google Scholar
• Mameli A, Barcellona D, Marongiu F. Rheumatoid arthritis and thrombosis. Clin Exp Rheumatol. 2009;27(5):846–855.
   PubMed Web of Science ®Google Scholar
• Wallberg-Jonsson S, Cvetkovic JT, Sundqvist KG, Lefvert AK, Rantapaa-Dahlqvist S. Activation of the immune system and inflammatory activity in relation to markers of atherothrombotic disease and atherosclerosis in rheumatoid arthritis. J Rheumatol. 2002;29(5):875–882.
   PubMed Web of Science ®Google Scholar
• Fox EA, Kahn SR. The relationship between inflammation and venous thrombosis. A systematic review of clinical studies. Thromb Haemost. 2005;94(2):362–365. doi:10.1160/TH05-04-0266
   PubMed Web of Science ®Google Scholar
• Zacharski LR, Brown FE, Memoli VA, et al. Pathways of coagulation activation in situ in rheumatoid synovial tissue. Clin Immunol Immunopathol. 1992;63(2):155–162. doi:10.1016/0090-1229(92)90008-C
   PubMedGoogle Scholar
• Yxfeldt A, Wallberg-Jonsson S, Hultdin J, Rantapaa-Dahlqvist S. Homocysteine in patients with rheumatoid arthritis in relation to inflammation and B-vitamin treatment. Scand J Rheumatol. 2003;32(4):205–210. doi:10.1080/03009740310003686
   PubMed Web of Science ®Google Scholar
• Welch GN, Loscalzo J. Homocysteine and atherothrombosis. N Engl J Med. 1998;338(15):1042–1050. doi:10.1056/NEJM199804093381507
   PubMed Web of Science ®Google Scholar
• Ardoin SP, Shanahan JC, Pisetsky DS. The role of microparticles in inflammation and thrombosis. Scand J Immunol. 2007;66(2–3):159–165. doi:10.1111/j.1365-3083.2007.01984.x
   PubMed Web of Science ®Google Scholar
• Antonopoulos CN, Sfyroeras GS, Kakisis JD, Moulakakis KG, Liapis CD. The role of soluble P selectin in the diagnosis of venous thromboembolism. Thromb Res. 2014;133(1):17–24. doi:10.1016/j.thromres.2013.08.014
   PubMed Web of Science ®Google Scholar
• Schmitt-Sody M, Metz P, Gottschalk O, et al. Platelet P-selectin is significantly involved in leukocyte-endothelial cell interaction in murine antigen-induced arthritis. Platelets. 2007;18(5):365–372. doi:10.1080/09537100701191315
   PubMed Web of Science ®Google Scholar
• Ertenli I, Kiraz S, Arici M, et al. P-selectin as a circulating molecular marker in rheumatoid arthritis with thrombocytosis. J Rheumatol. 1998;25(6):1054–1058.
   PubMed Web of Science ®Google Scholar
• Xu J, Jin J, Tan S. Association of thrombomodulin gene polymorphisms with susceptibility to atherosclerotic diseases: a meta-analysis. Ann Hum Genet. 2016;80(3):172–181. doi:10.1111/ahg.12148
   PubMed Web of Science ®Google Scholar
• Weiler H, Isermann BH. Thrombomodulin. J Thromb Haemost. 2003;1(7):1515–1524. doi:10.1046/j.1538-7836.2003.00306.x
   PubMed Web of Science ®Google Scholar
• Esmon CT. The impact of the inflammatory response on coagulation. Thromb Res. 2004;114(5–6):321–327. doi:10.1016/j.thromres.2004.06.028
   PubMed Web of Science ®Google Scholar
• Hoppe B, Dorner T. Coagulation and the fibrin network in rheumatic disease: a role beyond haemostasis. Nat Rev Rheumatol. 2012;8(12):738–746. doi:10.1038/nrrheum.2012.184
   PubMed Web of Science ®Google Scholar
• Sillen M, Declerck PJ. Thrombin Activatable Fibrinolysis Inhibitor (TAFI): an Updated Narrative Review. Int J Mol Sci. 2021;22(7):3670. doi:10.3390/ijms22073670
   PubMed Web of Science ®Google Scholar
• So AK, Varisco PA, Kemkes-Matthes B, et al. Arthritis is linked to local and systemic activation of coagulation and fibrinolysis pathways. J Thromb Haemost. 2003;1(12):2510–2515. doi:10.1111/j.1538-7836.2003.00462.x
   PubMed Web of Science ®Google Scholar
• Peters MJ, Nurmohamed MT, van Eijk IC, Verkleij CJ, Marx PF. Thrombin-activatable fibrinolysis inhibitor and its relation with inflammation in rheumatoid arthritis. Ann Rheum Dis. 2009;68(7):1232–1233. doi:10.1136/ard.2008.097485
   PubMed Web of Science ®Google Scholar
• Esmon CT. The interactions between inflammation and coagulation. Br J Haematol. 2005;131(4):417–430. doi:10.1111/j.1365-2141.2005.05753.x
   PubMed Web of Science ®Google Scholar
• Giannakopoulos B, Passam F, Rahgozar S, Krilis SA. Current concepts on the pathogenesis of the antiphospholipid syndrome. Blood. 2007;109(2):422–430. doi:10.1182/blood-2006-04-001206
   PubMed Web of Science ®Google Scholar
• Jurado M, Páramo JA, Gutierrez-Pimentel M, Rocha E. Fibrinolytic potential and antiphospholipid antibodies in systemic lupus erythematosus and other connective tissue disorders. Thromb Haemost. 1992;68(5):516–520. doi:10.1055/s-0038-1646310
   PubMed Web of Science ®Google Scholar
• Fort JG, Cowchock FS, Abruzzo JL, Smith JB. Anticardiolipin antibodies in patients with rheumatic diseases. Arthritis Rheum. 1987;30(7):752–760. doi:10.1002/art.1780300705
   PubMed Web of Science ®Google Scholar
• Seriolo B, Accardo S, Garnero A, Fasciolo D, Cutolo M. Anticardiolipin antibodies, free protein S levels and thrombosis: a survey in a selected population of rheumatoid arthritis patients. Rheumatology. 1999;38(7):675–678. doi:10.1093/rheumatology/38.7.675
   PubMed Web of Science ®Google Scholar
• Gladd DA, Olech E. Antiphospholipid antibodies in rheumatoid arthritis: identifying the dominoes. Curr Rheumatol Rep. 2009;11(1):43–51. doi:10.1007/s11926-009-0007-3
   PubMedGoogle Scholar
• Cheng YJ, Liu ZH, Yao FJ, et al. Current and former smoking and risk for venous thromboembolism: a systematic review and meta-analysis. PLoS Med. 2013;10(9):e1001515. doi:10.1371/journal.pmed.1001515
   PubMed Web of Science ®Google Scholar
• Di Giuseppe D, Discacciati A, Orsini N, Wolk A. Cigarette smoking and risk of rheumatoid arthritis: a dose-response meta-analysis. Arthritis Res Ther. 2014;16(2):R61. doi:10.1186/ar4498
   PubMed Web of Science ®Google Scholar
• Smith BD, La Celle PL. Blood viscosity and thrombosis: clinical considerations. Prog Hemost Thromb. 1982;6:179–201.
   PubMedGoogle Scholar
• Bombardier C, Barbieri M, Parthan A, et al. The relationship between joint damage and functional disability in rheumatoid arthritis: a systematic review. Ann Rheum Dis. 2012;71(6):836–844. doi:10.1136/annrheumdis-2011-200343
   PubMed Web of Science ®Google Scholar
• Ravi B, Escott B, Shah PS, et al. A systematic review and meta-analysis comparing complications following total joint arthroplasty for rheumatoid arthritis versus for osteoarthritis. Arthritis Rheum. 2012;64(12):3839–3849. doi:10.1002/art.37690
   PubMed Web of Science ®Google Scholar
• Singh JA, Cameron C, Noorbaloochi S, et al. Risk of serious infection in biological treatment of patients with rheumatoid arthritis: a systematic review and meta-analysis. Lancet. 2015;386(9990):258–265. doi:10.1016/S0140-6736(14)61704-9
   PubMed Web of Science ®Google Scholar
• Gupta A, Pipe SG, Towheed T, Anastassiades T. Is rheumatoid arthritis a risk factor for fractures: a systematic review of observational studies. Curr Rheumatol Rev. 2020;16(1):29–37. doi:10.2174/1573397115666190723160312
   PubMed Web of Science ®Google Scholar
• Restivo V, Candiloro S, Daidone M, et al. Systematic review and meta-analysis of cardiovascular risk in rheumatological disease: symptomatic and non-symptomatic events in rheumatoid arthritis and systemic lupus erythematosus. Autoimmun Rev. 2022;21(1):102925.
   PubMed Web of Science ®Google Scholar
• Ungprasert P, Srivali N, Cheungpasitporn W, Davis Iii JM. Risk of incident chronic obstructive pulmonary disease in patients with rheumatoid arthritis: a systematic review and meta-analysis. Joint Bone Spine. 2016;83(3):290–294. doi:10.1016/j.jbspin.2015.05.016
   PubMed Web of Science ®Google Scholar
• Lee JJ, Pope JE. A meta-analysis of the risk of venous thromboembolism in inflammatory rheumatic diseases. Arthritis Res Ther. 2014;16(5):435. doi:10.1186/s13075-014-0435-y
   PubMed Web of Science ®Google Scholar
• Bacani AK, Gabriel SE, Crowson CS, Heit JA, Matteson EL. Noncardiac vascular disease in rheumatoid arthritis: increase in venous thromboembolic events? Arthritis Rheum. 2012;64(1):53–61. doi:10.1002/art.33322
   PubMed Web of Science ®Google Scholar
• Ramagopalan SV, Wotton CJ, Handel AE, Yeates D, Goldacre MJ. Risk of venous thromboembolism in people admitted to hospital with selected immune-mediated diseases: record-linkage study. BMC Med. 2011;9:1. doi:10.1186/1741-7015-9-1
   PubMed Web of Science ®Google Scholar
• Choi HK, Rho YH, Zhu Y, Cea-Soriano L, Avina-Zubieta JA, Zhang Y. The risk of pulmonary embolism and deep vein thrombosis in rheumatoid arthritis: a UK population-based outpatient cohort study. Ann Rheum Dis. 2013;72(7):1182–1187. doi:10.1136/annrheumdis-2012-201669
   PubMed Web of Science ®Google Scholar
• Chung WS, Peng CL, Lin CL, et al. Rheumatoid arthritis increases the risk of deep vein thrombosis and pulmonary thromboembolism: a nationwide cohort study. Ann Rheum Dis. 2014;73(10):1774–1780. doi:10.1136/annrheumdis-2013-203380
   PubMed Web of Science ®Google Scholar
• Li L, Lu N, Avina-Galindo AM, et al. The risk and trend of pulmonary embolism and deep vein thrombosis in rheumatoid arthritis: a general population-based study. Rheumatology. 2021;60(1):188–195. doi:10.1093/rheumatology/keaa262
   PubMed Web of Science ®Google Scholar
• Ozen G, Pedro S, Schumacher R, Simon T, Michaud K. Risk factors for venous thromboembolism and atherosclerotic cardiovascular disease: do they differ in patients with rheumatoid arthritis? RMD Open. 2021;7(2):e001618. doi:10.1136/rmdopen-2021-001618
   PubMed Web of Science ®Google Scholar
• Molander V, Bower H, Frisell T, Askling J. Risk of venous thromboembolism in rheumatoid arthritis, and its association with disease activity: a nationwide cohort study from Sweden. Ann Rheum Dis. 2021;80(2):169–175. doi:10.1136/annrheumdis-2020-218419
   PubMed Web of Science ®Google Scholar
• Conforti A, Berardicurti O, Pavlych V, Di Cola I, Cipriani P, Ruscitti P. Incidence of venous thromboembolism in rheumatoid arthritis, results from a ”real-life” cohort and an appraisal of available literature. Medicine. 2021;100(33):e26953. doi:10.1097/MD.0000000000026953
   PubMed Web of Science ®Google Scholar
• Holmqvist ME, Neovius M, Eriksson J, et al. Risk of venous thromboembolism in patients with rheumatoid arthritis and association with disease duration and hospitalization. JAMA. 2012;308(13):1350–1356. doi:10.1001/2012.jama.11741
   PubMed Web of Science ®Google Scholar
• Yusuf HR, Hooper WC, Beckman MG, Zhang QC, Tsai J, Ortel TL. Risk of venous thromboembolism among hospitalizations of adults with selected autoimmune diseases. J Thromb Thrombolysis. 2014;38(3):306–313. doi:10.1007/s11239-014-1050-0
   PubMed Web of Science ®Google Scholar
• Galloway J, Barrett K, Irving P, et al. Risk of venous thromboembolism in immune-mediated inflammatory diseases: a UK matched cohort study. RMD Open. 2020;6(3):e001392. doi:10.1136/rmdopen-2020-001392
   PubMed Web of Science ®Google Scholar
• Kim SC, Schneeweiss S, Liu J, Solomon DH. Risk of venous thromboembolism in patients with rheumatoid arthritis. Arthritis Care Res. 2013;65(10):1600–1607. doi:10.1002/acr.22039
   PubMed Web of Science ®Google Scholar
• Sadra V, Khabbazi A, Kolahi S, Hajialiloo M, Ghojazadeh M. Randomized double-blind study of the effect of dexamethasone and methylprednisolone pulse in the control of rheumatoid arthritis flare-up: a preliminary study. Int J Rheum Dis. 2014;17(4):389–393. doi:10.1111/1756-185X.12278
   PubMed Web of Science ®Google Scholar
• Hua C, Buttgereit F, Combe B. Glucocorticoids in rheumatoid arthritis: current status and future studies. RMD Open. 2020;6(1):e000536. doi:10.1136/rmdopen-2017-000536
   PubMed Web of Science ®Google Scholar
• Johannesdottir SA, Horváth-Puhó E, Dekkers OM, et al. Use of glucocorticoids and risk of venous thromboembolism: a nationwide population-based case-control study. JAMA Intern Med. 2013;173(9):743–752. doi:10.1001/jamainternmed.2013.122
   PubMed Web of Science ®Google Scholar
• Coelho MC, Santos CV, Vieira Neto L, Gadelha MR. Adverse effects of glucocorticoids: coagulopathy. Eur J Endocrinol. 2015;173(4):M11–21. doi:10.1530/EJE-15-0198
   PubMed Web of Science ®Google Scholar
• Chen CP, Kung PT, Chou WY, Tsai WC. Effect of introducing biologics to patients with rheumatoid arthritis on the risk of venous thromboembolism: a nationwide cohort study. Sci Rep. 2021;11(1):17009. doi:10.1038/s41598-021-96508-z
   PubMed Web of Science ®Google Scholar
• Sepriano A, Kerschbaumer A, Smolen JS, et al. Safety of synthetic and biological DMARDs: a systematic literature review informing the 2019 update of the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis. 2020;79(6):760–770. doi:10.1136/annrheumdis-2019-216653
   PubMed Web of Science ®Google Scholar
• Davies R, Galloway JB, Watson KD, Lunt M, Symmons DP, Hyrich KL. Venous thrombotic events are not increased in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis. 2011;70(10):1831–1834. doi:10.1136/ard.2011.153536
   PubMed Web of Science ®Google Scholar
• Ketfi C, Boutigny A, Mohamedi N, et al. Risk of venous thromboembolism in rheumatoid arthritis. Joint Bone Spine. 2021;88(3):105122. doi:10.1016/j.jbspin.2020.105122
   PubMed Web of Science ®Google Scholar
• Kotyla PJ, Engelmann M, Giemza-Stokłosa J, Wnuk B, Islam MA. Thromboembolic Adverse Drug Reactions in Janus Kinase (JAK) Inhibitors: does the Inhibitor Specificity Play a Role? Int J Mol Sci. 2021;22(5):2449. doi:10.3390/ijms22052449
   PubMed Web of Science ®Google Scholar
• Mease P, Charles-Schoeman C, Cohen S, et al. Incidence of venous and arterial thromboembolic events reported in the tofacitinib rheumatoid arthritis, psoriasis and psoriatic arthritis development programmes and from real-world data. Ann Rheum Dis. 2020;79(11):1400–1413. doi:10.1136/annrheumdis-2019-216761
   PubMed Web of Science ®Google Scholar
• Ytterberg SR, Bhatt DL, Mikuls TR, et al. Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis. N Engl J Med. 2022;386(4):316–326. doi:10.1056/NEJMoa2109927
   PubMed Web of Science ®Google Scholar
• Alves C, Penedones A, Mendes D, Marques FB. Risk of Cardiovascular and Venous Thromboembolic Events Associated With Janus Kinase Inhibitors in Rheumatoid Arthritis: a Systematic Review and Network Meta-analysis. J Clin Rheumatol. 2022;28(2):69–76. doi:10.1097/RHU.0000000000001804
   PubMed Web of Science ®Google Scholar
• Bilal J, Riaz IB, Naqvi SAA, et al. Janus Kinase Inhibitors and Risk of Venous Thromboembolism: a Systematic Review and Meta-analysis. Mayo Clin Proc. 2021;96(7):1861–1873. doi:10.1016/j.mayocp.2020.12.035
   PubMed Web of Science ®Google Scholar
• Giménez Poderós T, Gallardo Borge S, Vazquez-Ferreiro P. Risk of Venous Thromboembolism Associated With Tofacitinib and Baricitinib: a Systematic Review and Indirect Meta-Analysis. Pharmacotherapy. 2020;40(12):1248–1264. doi:10.1002/phar.2472
   PubMed Web of Science ®Google Scholar
• Yates M, Mootoo A, Adas M, et al. Venous thromboembolism risk with jak inhibitors: a meta-analysis. Arthritis Rheumatol. 2021;73(5):779–788. doi:10.1002/art.41580
   PubMed Web of Science ®Google Scholar
• Wang F, Sun L, Wang S, et al. Efficacy and safety of tofacitinib, baricitinib, and upadacitinib for rheumatoid arthritis: a systematic review and meta-analysis. Mayo Clin Proc. 2020;95(7):1404–1419. doi:10.1016/j.mayocp.2020.01.039
   PubMed Web of Science ®Google Scholar
• Xie W, Xiao S, Huang Y, Sun X, Zhang Z. Effect of tofacitinib on cardiovascular events and all-cause mortality in patients with immune-mediated inflammatory diseases: a systematic review and meta-analysis of randomized controlled trials. Ther Adv Musculoskelet Dis. 2019;11:1759720x19895492. doi:10.1177/1759720X19895492
   PubMed Web of Science ®Google Scholar
• Xie W, Huang Y, Xiao S, Sun X, Fan Y, Zhang Z. Impact of Janus kinase inhibitors on risk of cardiovascular events in patients with rheumatoid arthritis: systematic review and meta-analysis of randomised controlled trials. Ann Rheum Dis. 2019;78(8):1048–1054. doi:10.1136/annrheumdis-2018-214846
   PubMed Web of Science ®Google Scholar
• Mori S, Ogata F, Tsunoda R. Risk of venous thromboembolism associated with Janus kinase inhibitors for rheumatoid arthritis: case presentation and literature review. Clin Rheumatol. 2021;40(11):4457–4471. doi:10.1007/s10067-021-05911-4
   PubMed Web of Science ®Google Scholar
• Matta F, Singala R, Yaekoub AY, Najjar R, Stein PD. Risk of venous thromboembolism with rheumatoid arthritis. Thromb Haemost. 2009;101(1):134–138. doi:10.1160/TH08-08-0551
   PubMed Web of Science ®Google Scholar
• Kang JH, Keller JJ, Lin YK, Lin HC. A population-based case-control study on the association between rheumatoid arthritis and deep vein thrombosis. J Vasc Surg. 2012;56(6):1642–1648. doi:10.1016/j.jvs.2012.05.087
   PubMed Web of Science ®Google Scholar
• Yusuf HR, Hooper WC, Grosse SD, Parker CS, Boulet SL, Ortel TL. Risk of venous thromboembolism occurrence among adults with selected autoimmune diseases: a study among a U.S. cohort of commercial insurance enrollees. Thromb Res. 2015;135(1):50–57. doi:10.1016/j.thromres.2014.10.012
   PubMed Web of Science ®Google Scholar
• Ogdie A, Kay McGill N, Shin DB, et al. Risk of venous thromboembolism in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: a general population-based cohort study. Eur Heart J. 2018;39(39):3608–3614. doi:10.1093/eurheartj/ehx145
   PubMed Web of Science ®Google Scholar
• Mansour R, Azrielant S, Watad A, et al. Venous thromboembolism events among RA patients. Mediterr J Rheumatol. 2019;30(1):38–43. doi:10.31138/mjr.30.1.38
   PubMedGoogle Scholar
• Dore RK, Antonova JN, Burudpakdee C, et al. Prevalence, and Associated Costs of Anemia, Malignancy, Venous Thromboembolism, Major Adverse Cardiovascular Events, and Infections in Rheumatoid Arthritis Patients by Treatment History in the United States. ACR Open Rheumatol. 2022;4(6):473–482. doi:10.1002/acr2.11376
   PubMedGoogle Scholar